Patents by Inventor Upender Velaparthi

Upender Velaparthi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20090239838
    Abstract: The invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity thereby making them useful as anticancer agents and for the treatment of Alzheimer's Disease.
    Type: Application
    Filed: March 26, 2009
    Publication date: September 24, 2009
    Inventors: Mark D. Wittman, Harold Mastalerz, Kurt Zimmermann, Mark G. Saulnier, Upender Velaparthi, Dolatrai M. Vyas, Guifen Zhang, Walter Lewis Johnson, David B. Frennesson, Xiaopeng Sang, Peiying Liu, David R. Langley
  • Patent number: 7534792
    Abstract: The invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity thereby making them useful as anticancer agents and for the treatment of Alzheimer's Disease.
    Type: Grant
    Filed: July 5, 2007
    Date of Patent: May 19, 2009
    Assignee: Bristol-Myers Squibb Company
    Inventors: Mark D. Wittman, Harold Mastalerz, Kurt Zimmermann, Mark G. Saulnier, Upender Velaparthi, Dolatrai M. Vyas, Guifen Zhang, Walter Lewis Johnson, David B. Frennesson, Xiaopeng Sang, Peiying Liu, David R. Langley
  • Patent number: 7470696
    Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase enzymes thereby making them useful as anti-cancer agents.
    Type: Grant
    Filed: January 23, 2007
    Date of Patent: December 30, 2008
    Assignee: Bristol-Myers Squibb Company
    Inventors: Francis Beaulieu, Carl Ouellet, Kurt Zimmermann, Upender Velaparthi, Mark D. Wittman
  • Publication number: 20080009497
    Abstract: The invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity thereby making them useful as anticancer agents and for the treatment of Alzheimer's Disease.
    Type: Application
    Filed: July 5, 2007
    Publication date: January 10, 2008
    Inventors: Mark D. Wittman, Harold Mastalerz, Kurt Zimmermann, Mark G. Saulnier, Upender Velaparthi, Dolatrai M. Vyas, Guifen Zhang, Walter Lewis Johnson, David B. Frennesson, Xiaopeng Sang, Peiying Liu, David R. Langley
  • Patent number: 7232826
    Abstract: The present invention provides compounds of Formula I or II that are useful as anti-cancer agents and other diseases that can be treated by inhibiting tyrosine kinase enzymes
    Type: Grant
    Filed: September 29, 2003
    Date of Patent: June 19, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: Upender Velaparthi, Mark D. Wittman
  • Publication number: 20070135443
    Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase enzymes thereby making them useful as anti-cancer agents.
    Type: Application
    Filed: January 23, 2007
    Publication date: June 14, 2007
    Inventors: Francis Beaulieu, Carl Ouellet, Kurt Zimmermann, Upender Velaparthi, Mark Wittman
  • Patent number: 7223757
    Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase enzymes thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases which can be treated by inhibiting tyrosine kinase enzymes.
    Type: Grant
    Filed: November 30, 2005
    Date of Patent: May 29, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: Mark D. Wittman, Neelakantan Balasubramanian, Upender Velaparthi, Kurt Zimmermann, Mark G. Saulnier, Peiying Liu, Xiaopeng Sang, David B. Frennesson, Karen M. Stoffan, James G. Tarrant, Anne Marinier, Stephan Roy
  • Patent number: 7189716
    Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase enzymes thereby making them useful as anti-cancer agents.
    Type: Grant
    Filed: January 5, 2004
    Date of Patent: March 13, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: Francis Beaulieu, Carl Ouellet, Kurt Zimmermann, Upender Velaparthi, Mark D. Wittman
  • Patent number: 7081454
    Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase enzymes thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases which can be treated by inhibiting tyrosine kinase enzymes.
    Type: Grant
    Filed: October 2, 2002
    Date of Patent: July 25, 2006
    Assignee: Bristol-Myers Squibb Co.
    Inventors: Mark D. Wittman, Neelakantan Balasubramanian, Upender Velaparthi, Kurt Zimmermann, Mark G. Saulnier, Peiying Liu, Xiaopeng Sang, David B. Frennesson, Karen M. Stoffan, James G. Tarrant, Anne Marinier, Stephan Roy
  • Publication number: 20060079518
    Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase enzymes thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases which can be treated by inhibiting tyrosine kinase enzymes.
    Type: Application
    Filed: November 30, 2005
    Publication date: April 13, 2006
    Inventors: Mark Wittman, Neelakantan Balasubramanian, Upender Velaparthi, Kurt Zimmermann, Mark Saulnier, Peiying Liu, Xiaopeng Sang, David Frennesson, Karen Stoffan, James Tarrant, Anne Marinier, Stephan Roy
  • Publication number: 20040180897
    Abstract: The present invention provides compounds of formula I 1
    Type: Application
    Filed: January 5, 2004
    Publication date: September 16, 2004
    Inventors: Francis Beaulieu, Carl Ouellet, Kurt Zimmermann, Upender Velaparthi, Mark D. Wittman
  • Publication number: 20040092514
    Abstract: The present invention provides compounds of Formula I or II that are useful as anti-cancer agents and other diseases that can be treated by inhibiting tyrosine kinase enzymes.
    Type: Application
    Filed: September 29, 2003
    Publication date: May 13, 2004
    Inventors: Upender Velaparthi, Mark D. Wittman
  • Publication number: 20040044203
    Abstract: The present invention provides compounds of formula I 1
    Type: Application
    Filed: October 2, 2002
    Publication date: March 4, 2004
    Inventors: Mark D. Wittman, Neelakantan Balasubramanian, Upender Velaparthi, Kurt Zimmermann, Mark G. Saulnier, Peiying Liu, Xiaopeng Sang, David B. Frennesson, Karen M. Stoffan, James G. Tarrant, Anne Marinier, Stephan Roy